Jubilant Organosys Ltd. announced today that its subsidiary Clinsys Clinical Research, Inc.(R), New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics(R) from TrialStat(R) for a purchase consideration of CAD 750,000.

TrialStat ClinicalAnalytics (TrialStat CA) is a Web-based electronic data capture (EDC) solution currently used by a wide range of pharmaceutical and CRO customers worldwide. TrialStat CA is the industry's first EDC platform to allow all aspects of a study to be configured, deployed and managed through a browser interface, enabling customers to start their studies quickly and cost-effectively.

Clinsys extensive global resources will enable TrialStat to continue its proven record of growth, customer service and product innovation. This agreement will give TrialStat's existing CRO and biopharmaceutical customer base a broader scope of services.

"The Company had identified TrialStat ClinicalAnalytics as one of the most innovative EDC solutions on the market and was determined to include it in its offerings to its customers globally," said David E. Williams, Chief Executive Officer of Clinsys.

Commenting on the acquisition, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd., said, "The addition of the TrialStat CA and its proven EDC offering will allow Clinsys to continue to expand its integrated solutions for pharmaceutical, biotechnology and medical device organizations. This acquisition is an excellent fit and addresses the industry's continuously evolving requirements in EDC."